ADRB3 and overactive bladder: An important strength of the approach we propose, which could favour clinical studies in patients with X‐NDI, is the fact that mirabegron, a specific human β3‐AR agonist, is already approved for clinical use in the treatment of overactive bladder (OAB).28, 34, 35, 36, 37, 38, 39